CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
Ethinylestradiol / Norethisterone +1 moredrug
Likely dose
Ethinylestradiol / Norethisterone 30mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00732693
NCT00732693Phase 4Completed
CompareCT.gov

Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters

University of Edinburgh·interventional·Posted Aug 12, 2008·Updated Aug 12, 2008

In Brief

A Phase 4 clinical trial evaluating Ethinylestradiol / Norethisterone and Estradiol / Progesterone for Premature Ovarian Failure. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

The aim of the study is to determine whether physiological sex steroid replacement improves parameters of skeletal, cardiovascular and reproductive health of women treated with current sex steroid replacement regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPremature Ovarian Failure
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 12, 2008
Enrollment StartFeb 1, 2002
Primary CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.9 years ago

Interventions

Ethinylestradiol / Norethisteronedrug

Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 "pill free" days

Estradiol / Progesteronedrug

Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4